VIVES LOUVAIN TECHNOLOGY FUND
Vives is an interregional seed and early stage technology multi-sector fund. The new fund, initiated by UCLouvain, is a unique European inter-university fund having access to world class innovations from leading EU top universities.
VIVES LOUVAIN TECHNOLOGY FUND
Industry:
Venture Capital
Founded:
2011-01-01
Status:
Active
Contact:
+32.472.206.355
Email Addresses:
[email protected]
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager Content Delivery Network
Similar Organizations
Detroit Venture Partners
Detroit Venture Partners is an American venture capital firm that funds seed- and early-stage technology companies.
Tahoma Ventures
Tahoma Ventures provides early stage capital to IT technology startups.
Current Employees Featured
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2021-12-15 | Sunrise | Vives Louvain Technology Fund investment in Seed Round - Sunrise | 6.5 M EUR |
| 2021-10-28 | Novadip Biosciences | Vives Louvain Technology Fund investment in Series B - Novadip Biosciences | 19 M EUR |
| 2021-04-14 | Aphea.Bio | Vives Louvain Technology Fund investment in Series B - Aphea.Bio | 18 M EUR |
| 2021-04-01 | Aphea.Bio | Vives Louvain Technology Fund investment in Series B - Aphea.Bio | 4 M EUR |
| 2020-09-28 | Syndesi Therapeutics | Vives Louvain Technology Fund investment in Series A - Syndesi Therapeutics | 6 M EUR |
| 2020-07-28 | ExeVir Bio | Vives Louvain Technology Fund investment in Series A - ExeVir Bio | 42 M EUR |
| 2020-07-02 | e-peas | Vives Louvain Technology Fund investment in Venture Round - e-peas | 8 M EUR |
| 2020-04-01 | ITeos Therapeutics | Vives Louvain Technology Fund investment in Series B - ITeos Therapeutics | 125 M USD |
| 2018-03-22 | Tessares | Vives Louvain Technology Fund investment in Venture Round - Tessares | 3 M EUR |
| 2018-02-15 | Syndesi Therapeutics | Vives Louvain Technology Fund investment in Series A - Syndesi Therapeutics | 17 M EUR |